Is Shopify Stock Still a Buy in 2025 or Has Growth Peaked?
The big picture trends in e‑commerce sales are clearly in…
Sell
46
CPHI Quote, Financials, Valuation and Earnings
Last price:
$1.82
Seasonality move
:
214.7%
Day range:
$1.83 - $1.97
52-week range:
$1.20 - $4.10
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.73x
P/B ratio:
0.80x
Volume:
53.1K
Avg. volume:
114.8K
1-year change:
-40.62%
Market cap:
$6.2M
Revenue:
$4.5M
EPS (TTM):
-$0.34
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, China Pharma Holding has -- downside to fair value with a price target of -- per share.
CPHI vs. S&P 500
-
Over the past 5 trading days, China Pharma Holding has underperformed the S&P 500 by -4.96% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
China Pharma Holding does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
China Pharma Holding revenues have been falling on a year-over-year basis for 7 quarters in a row. In the most recent quarter China Pharma Holding reported revenues of $1.1M.
Earnings Growth
-
China Pharma Holding earnings have been falling on a year-over-year basis for 6 quarters in a row. In the most recent quarter China Pharma Holding reported earnings per share of -$0.06.
Enterprise value:
9.1M
EV / Invested capital:
--
Price / LTM sales:
0.73x
EV / EBIT:
--
EV / Revenue:
2.01x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-11.99x
Price / Operating cash flow:
12.76x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$1.9M
Return On Assets:
-31.32%
Net Income Margin (TTM):
-85.56%
Return On Equity:
-66.27%
Return On Invested Capital:
-41.21%
Operating Margin:
-98.65%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $8.1M | $7M | $4.5M | $2.1M | $1.1M | |
| Gross Profit | -$493.9K | -$281.1K | -$2M | -$79.2K | -$160.6K | |
| Operating Income | -$3.6M | -$2.8M | -$4.6M | -$1.2M | -$1.2M | |
| EBITDA | -$837.7K | $8.4K | -$2M | -$486.1K | -$746.6K | |
| Diluted EPS | -$37.80 | -$10.46 | -$2.60 | -$1.16 | -$0.40 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $5.3M | $9.1M | $6M | $6M | $3.3M | |
| Total Assets | $21.1M | $22.6M | $17.8M | $16.5M | $14.9M | |
| Current Liabilities | $11.4M | $10.5M | $12.7M | $6.8M | $5M | |
| Total Liabilities | $13.1M | $16.6M | $13.5M | $9M | $7.1M | |
| Total Equity | $8M | $6M | $4.3M | $7.5M | $7.7M | |
| Total Debt | $7.4M | $12.4M | $8.7M | $4.5M | $3.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$409.5K | -$699.7K | -$466.4K | -$22.3K | $238.5K | |
| Cash From Investing | -$402K | -$11.5K | -$291.7K | -$4.5K | -$272.9K | |
| Cash From Financing | -$1.8M | $73.1K | $27.4K | $30.4K | $6.8K | |
| Free Cash Flow | -$811.5K | -$711.2K | -$758.1K | -$26.8K | -$34.4K | |
CPHI
Sector
Market Cap
$6.2M
$35.1M
Price % of 52-Week High
46.1%
44.56%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-40.62%
-40.62%
Beta (5-Year)
0.854
0.662
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.92
200-day SMA
Sell
Level
$2.14
Bollinger Bands (100)
Sell
Level
1.73 - 2.47
Chaikin Money Flow
Buy
Level
347.6K
20-day SMA
Buy
Level
$1.64
Relative Strength Index (RSI14)
Buy
Level
50.24
ADX Line
Buy
Level
22.97
Williams %R
Neutral
Level
-35.8696
50-day SMA
Sell
Level
$2.12
MACD (12, 26)
Sell
Level
-0.04
25-day Aroon Oscillator
Sell
Level
-16
On Balance Volume
Neutral
Level
5.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.3552)
Sell
CA Score
(Annual)
Level (-1.7395)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (3.6129)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.
Stock Forecast FAQ
In the current month, CPHI has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CPHI average analyst price target in the past 3 months is --.
-
Where Will China Pharma Holding Stock Be In 1 Year?
According to analysts, the consensus estimate is that China Pharma Holding share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About China Pharma Holding?
Analysts are divided on their view about China Pharma Holding share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that China Pharma Holding is a Sell and believe this share price will rise from its current level to --.
-
What Is China Pharma Holding's Price Target?
The price target for China Pharma Holding over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CPHI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for China Pharma Holding is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of CPHI?
You can purchase shares of China Pharma Holding via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase China Pharma Holding shares.
-
What Is The China Pharma Holding Share Price Today?
China Pharma Holding was last trading at $1.82 per share. This represents the most recent stock quote for China Pharma Holding. Yesterday, China Pharma Holding closed at $1.89 per share.
-
How To Buy China Pharma Holding Stock Online?
In order to purchase China Pharma Holding stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is RTX The Best Growth Stock?
Among the worldwide aerospace and defense markets, the US controls…
Is VFS Stock Cheap to Buy Now?
VinFast Auto (NASDAQ:VFS) is a leading EV manufacturer in Vietnam.…
Stock Ideas
Buy
71
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
63
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Buy
86
TRUP alert for May 6
Trupanion [TRUP] is up 0.25% over the past day.
Buy
60
RGC alert for May 6
Regencell Bioscience Holdings [RGC] is up 48.57% over the past day.
Sell
35
XYZ alert for May 6
Block [XYZ] is up 2.7% over the past day.
